[A22-95] Eptinezumab (migraine) - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2022
Project no.:
A22-95
Commission:
Commission awarded on 31.08.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Head and nerves
Indication:
Adult patients who have at least 4 migraine days per month
Result of dossier assessment:
- Untreated and pretreated patients for whom conventional migraine prophylaxis is an option: added benefit not proven
- Patients who do not respond to any of the following drug treatments/drug classes, for whom they are unsuitable, or who do not tolerate them: metoprolol, propranolol, flunarizine, topiramate, amitriptyline, clostridium botulinum toxin type A: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.